Bionomics License Oncology Drug Candidate BNC101 to Carina Biotech for CAR–T Therapy Development

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, today announced that it has entered into an exclusive Agreement to license Bionomics’ BNC101 oncology drug candidate to Carina Biotech (Carina), for the development of Chimeric Antigen Receptor T cell (CAR-T) therapy, which harnesses the body’s immune system to fight cancer.

BNC101 is a First-in-Class Humanized Monoclonal Antibody to LGR5, which is overexpressed in cancer stem cells within solid tumors including colorectal, breast, pancreatic, ovarian, lung, liver and gastric cancers and has the potential to guide CAR-T therapeutic development.

Under the worldwide, exclusive License Agreement, Carina will fund all research and development activities. Bionomics is eligible to receive up to A$118 million in clinical & development milestones plus royalty payments if Carina fully develops and markets the new therapy. In the event that Carina sub-licenses the CAR-T treatment, Bionomics is eligible to share in the sub-licensing revenues in early clinical development and receive a substantial double-digit portion of the revenues in later stages of clinical development.

Bionomics Executive Chairman Dr Errol De Souza said, “We are very excited to have entered into this agreement with Carina Biotech given the opportunity CAR-T therapy offers. This innovative approach has the potential to create a new cancer treatment. Bionomics retains BNC101 for other types of therapies and is continuing to search for such opportunities. This is in keeping with our corporate strategy to leverage value for our clinical oncology assets by working with other companies bringing proprietary technology to the table and providing full funding to progress development of our assets for the potential future benefit to patients and our shareholders.”

AUTHORISED BY THE BOARD

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis
Legal Counsel & Company Secretary
Bionomics Limited
31 Dalgleish St,
Thebarton, South Australia
+61 8 8354 6100
jmoschakis@bionomics.com.au
About Bionomics Limited
Bionomics (ASX: BNO, OTCQB:BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ drug candidates (including BNC210), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors’ drugs and drug candidates may vary from those reported when tested in different settings.